PrimeRFP SCOUT · Federal Contract Recompete Brief

W911SR22F0014 — CLINICAL DEVELOPMENT PHASE 2 STUDY

CLINICAL DEVELOPMENT PHASE 2 STUDY is a federal award for Department of Defense (DOD) held by OLOGY BIOSERVICES, INC.. Estimated value $107.9M ($93M obligated). Current period of performance ends Feb 29, 2028.

$107.9M
Estimated Value
$93M
Obligated
Feb 29, 2028
PoP End / Expires

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

OLOGY BIOSERVICES, INC. holds $17.9M across 7 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 2 related awards under parent W911SR22D0009. Recompete timing centers on the Feb 29, 2028 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

Federal
Contract numberW911SR22F0014
AgencyDepartment of Defense (DOD)
IncumbentOLOGY BIOSERVICES, INC.
UEIGC2RFAZK8G64
NAICS541715
PSCAN42
Parent IDIQ / IDVW911SR22D0009
PoP end (current)Feb 29, 2028
Obligated$93M

Recompete timing

Public
Expiring in 561 days

Current PoP ends Feb 29, 2028 (561 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Aug 29, 2026.

Watch this contract — one email →

Incumbent footprint

Public record

OLOGY BIOSERVICES, INC.$17.9M obligated across 7 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($17.9M) · all agencies
Department of Defense (DOD)$11.6M · 65%Department of Health and Human Services (HHS)$6.3M · 35%
Open full company profile

Related awards

Same parent · incumbent
W911SR23F0057
DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEV…
$67.6M
Jan 5, 2028
W911SR22F0073
DS PROCESS CHARACTERIZATION
$10.8M
Jan 5, 2028

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for W911SR22F0014
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open OLOGY BIOSERVICES, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract W911SR22F0014?

W911SR22F0014 (CLINICAL DEVELOPMENT PHASE 2 STUDY) is a Department of Defense (DOD) award with an estimated value of $107.9M, currently held by OLOGY BIOSERVICES, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on W911SR22F0014?

OLOGY BIOSERVICES, INC. is the incumbent with $17.9M across 7 related awards in SCOUT’s public footprint. The current period of performance ends Feb 29, 2028.

When does W911SR22F0014 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 29, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W911SR22D0009-W911SR22F0014